WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti® in China and several other Asia Pacific countries

WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries

Condividi: 31 dicembre 2020 STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ — Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand.
Ravicti® is in Europe and North America indicated for treatmeleggi di più…